Off-brand weight-loss drug makers are suing the FDA, again
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another lawsuit against the U.S. Food and Drug Administration (FDA). This time, it’s over the health regulator’s decision to remove semaglutide — the active ingredient in Novo Nordisk’s (NVO) popular…